PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors

PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors
Conditions:   Advanced Solid Tumors;   Gastric Cancer;   Gastroesophageal Junction Cancer;   Urothelial Cancer;   Non Small Cell Lung Cancer;   Head and Neck Squamous Cell Carcinomas
Interventions:   Drug: PF-07265028;   Biological: Sasanlimab
Sponsor:   Pfizer
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

March 9, 2022Comments OffClinicalTrials.gov | Gastroenterology Clinical Trials | Gastroenterology Studies | US National Library of Medicine
Comments